TREATMENT OF PSORIASIS AND PSORIATIC-ARTHRITIS WITH INTERFERON-GAMMA
TREATMENT OF PSORIASIS AND PSORIATIC-ARTHRITIS WITH INTERFERON-GAMMA
复制标题
DOI：
10.1111/1523-1747.ep12875040
复制
发表时间：
1990-12-01
影响因子：
6.5
通讯作者：
RASSNER, G
中科院分区：
文献类型：
--
作者：
FIERLBECK, G;RASSNER, G
在一项安慰剂对照双盲随机研究中，24 名银屑病关节炎患者接受了 28 天的治疗，而在一项开放研究中，56 名患者接受了 9 个月的治疗。 我们对患者进行每次皮下注射 100 μg IFN gamma 的治疗，前 2 周每天注射一次，然后每周 3 次。 评估关节炎治疗成功的主要标准是在双盲研究中里奇关节疼痛指数改善至少 25%，在长期研究中改善 30%。 在双盲研究中，干扰素组优于安慰剂组，卡方检验中单侧误差概率低于 5%，具有统计学显着性。 在长期研究中，IFN-γ 在治疗的前 3 个月内使部分患者的病情得到改善。 第三个月后没有观察到进一步的改善，在最初几个月被归类为有反应者的患者由于继续治疗而表现出病情恶化。 治疗期间体液炎症参数未正常化。 无法观察到皮肤表现的消退。 IFN γ 显然能够在注射部位诱发牛皮癣。 对长期治疗下的IFNγ血清水平、IFN抗体、血清中2'-5'A合成酶水平以及单核血细胞和NK细胞活性的调查显示，没有解释治疗3个月后疗效丧失的原因。
In a placebo-controlled double-blind randomized study, 24 patients with psoriatic arthritis were given 28 d of treatment, and in an open study, 56 patients were treated for 9 months. We treated patients with 100 mu-g IFN gamma per subcutaneous injections, which were given daily for the first 2 weeks and then 3 times per week. The principal criterion for evaluation of therapeutic success on arthritis was improvement of the Ritchie joint pain index by at least 25% in the double-blind and 30% in the long-term study. In the double-blind study, the interferon arm was superior to the placebo arm with a statistically significant, one-side error probability of less than 5% in the chi-square test. In the long-term study, IFN gamma caused an improvement in a portion of patients in the first 3 months of therapy. No further improvement was observed after the third month, and patients classified as responders in the first months showed a deterioration of the disease by continuing treatment. The humoral inflammatory parameters did not normalize during therapy. Regression of the skin manifestations could not be observed. IFN gamma is evidently capable of inducing a psoriasis on the injection site. Investigations of IFN gamma serum levels, IFN antibodies, 2'-5' A synthetase levels in serum, and mononuclear blood cells and NK cell activity under long-term therapy showed no explanation for the loss of efficacy after 3 months treatment.